Good Research Practice in Non-Clinical Pharmacology and Biomedicine.
Saved in:
Superior document: | Handbook of Experimental Pharmacology Series ; v.257 |
---|---|
: | |
TeilnehmendeR: | |
Place / Publishing House: | Cham : : Springer International Publishing AG,, 2020. Ã2020. |
Year of Publication: | 2020 |
Edition: | 1st ed. |
Language: | English |
Series: | Handbook of Experimental Pharmacology Series
|
Online Access: | |
Physical Description: | 1 online resource (424 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
5006120896 |
---|---|
ctrlnum |
(MiAaPQ)5006120896 (Au-PeEL)EBL6120896 (OCoLC)1143621169 |
collection |
bib_alma |
record_format |
marc |
spelling |
Bespalov, Anton. Good Research Practice in Non-Clinical Pharmacology and Biomedicine. 1st ed. Cham : Springer International Publishing AG, 2020. Ã2020. 1 online resource (424 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Handbook of Experimental Pharmacology Series ; v.257 Intro -- Preface -- Contents -- Quality in Non-GxP Research Environment -- 1 Why Do We Need a Quality Standard in Research? -- 2 Critical Points to Consider Before Implementing a Quality Standard in Research -- 2.1 GxP or Non-GxP Standard Implementation in Research? -- 2.1.1 Diverse Quality Mind-Set -- 2.2 Resource Constraints -- 3 Non-GxP Research Standard Basics -- 3.1 Data Integrity Principles: ALCOA+ -- 3.2 Research Quality System Core Elements -- 3.2.1 Management and Governance -- 3.2.2 Secure Research Documentation and Data Management -- 3.2.3 Method and Assay Qualification -- 3.2.4 Material, Reagents and Samples Management -- 3.2.5 Facility, Equipment and Computerized System Management -- 3.2.6 Personnel and Training Records Management -- 3.2.7 Outsourcing/External Collaborations -- 3.3 Risk- and Principle-Based Quality System Assessment Approach -- 4 How Can the Community Move Forward? -- 4.1 Promoting Quality Culture -- 4.1.1 Raising Scientist Awareness, Training and Mentoring -- 4.1.2 Empowering of Associates -- 4.1.3 Incentives for Behaviours Which Support Research Quality -- 4.1.4 Promoting a Positive Error Culture -- 4.2 Creating a Recognized Quality Standard in Research: IMI Initiative - EQIPD -- 4.3 Funders Plan to Enhance Reproducibility and Transparency -- 5 Conclusion -- References -- Guidelines and Initiatives for Good Research Practice -- 1 Introduction -- 2 Guidelines and Resources Aimed at Improving Reproducibility and Robustness in Preclinical Data -- 2.1 Funders/Granting Agencies/Policy Makers -- 2.2 Publishers/Journal Groups -- 2.3 Summary of Overarching Themes -- 3 Gaps and Looking to the Future -- References -- Learning from Principles of Evidence-Based Medicine to Optimize Nonclinical Research Practices -- 1 Introduction. 2 Current Context of Nonclinical, Nonregulated Experimental Pharmacology Study Conduct: Purposes and Processes Across Sectors -- 2.1 Outcomes and Deliverables of Nonclinical Pharmacology Studies in Industry and Academia -- 2.2 Scientific Integrity: Responsible Conduct of Research and Awareness of Cognitive Bias -- 2.3 Initiating a Research Project and Documenting Prior Evidence -- 2.4 Existence and Use of Guidelines -- 2.5 Use of Experimental Bias Reduction Measures in Study Design and Execution -- 2.6 Biostatistics: Access and Use to Enable Appropriate Design of Nonclinical Pharmacology Studies -- 2.7 Data Integrity, Reporting, and Sharing -- 3 Overcoming Obstacles and Further Learning from Principles of Evidence-Based Medicine -- 3.1 Working Together to Improve Nonclinical Data Reliability -- 3.2 Enhancing Capabilities, from Training to Open Access to Data -- 4 Conclusion and Perspectives -- References -- General Principles of Preclinical Study Design -- 1 An Overview -- 2 General Scientific Methods for Designing In Vivo Experiments -- 2.1 Hypotheses and Effect Size -- 2.2 Groups, Experimental Unit and Sample Size -- 2.3 Measurements and Outcome Measures -- 2.4 Independent Variables and Analysis -- 3 Experimental Biases: Definitions and Methods to Reduce Them -- 4 Experimental Biases: Major Domains and General Principles -- 5 Existing Guidelines and How to Use Them -- 6 Exploratory and Confirmatory Research -- References -- Resolving the Tension Between Exploration and Confirmation in Preclinical Biomedical Research -- 1 Introduction -- 2 Discrimination Between Exploration and Confirmation -- 3 Exploration Must Lead to a High Rate of False Positives -- 4 The Garden of Forking Paths -- 5 Confirmation Must Weed Out the False Positives of Exploration -- 6 Exact Replication Does Not Equal Confirmation. 7 Design, Analysis, and Interpretation of Exploratory vs Confirmatory Studies -- 8 No Publication Without Confirmation? -- 9 Team Science and Preclinical Multicenter Trials -- 10 Resolving the Tension Between Exploration and Confirmation -- References -- Blinding and Randomization -- 1 Randomization and Blinding: Need for Disambiguation -- 2 Randomization -- 2.1 Varieties of Randomization -- 2.1.1 Simple Randomization -- 2.1.2 Block Randomization -- 2.1.3 Stratified Randomization -- 2.1.4 The Case of Within-Subject Study Designs -- 2.2 Tools to Conduct Randomization -- 2.3 Randomization: Exceptions and Special Cases -- 3 Blinding -- 3.1 Fit-for-Purpose Blinding -- 3.1.1 Assumed Blinding -- 3.1.2 Partial Blinding -- 3.1.3 Full Blinding -- 3.2 Implementation of Blinding -- 4 Concluding Recommendations -- References -- Out of Control? Managing Baseline Variability in Experimental Studies with Control Groups -- 1 What Are Control Groups? -- 2 Basic Considerations for Control Groups -- 2.1 Attribution of Animals to Control Groups -- 2.2 What Group Size for Control Groups? -- 2.3 Controls and Blinding -- 3 Primary Controls -- 3.1 Choosing Appropriate Control Treatments: Not All Negative Controls Are Equal -- 3.2 Vehicle Controls -- 3.3 Sham Controls -- 3.4 Non-neutral Control Groups -- 3.5 Controls for Mutant, Transgenic and Knockout Animals -- 4 Positive Controls -- 5 Secondary Controls -- 5.1 Can Baseline Values Be Used as Control? -- 5.2 Historical Control Values -- 6 When Are Control Groups Not Necessary? -- 7 Conclusion -- References -- Quality of Research Tools -- 1 Introduction -- 2 Drugs in the Twenty-First Century -- 2.1 Chemical Tools Versus Drugs -- 3 First Things First: Identity and Purity -- 3.1 The Case of Evans Blue -- 3.2 Identity and Purity of Research Reagents -- 4 Drug Specificity or Drug Selectivity? -- 5 Species Selectivity. 5.1 Animal Strain and Preclinical Efficacy Using In Vivo Models -- 5.2 Differences in Sequence of Biological Target -- 5.3 Metabolism -- 6 What We Dose Is Not Always Directly Responsible for the Effects We See -- 6.1 Conditions Where In Vitro Potency Measures Do Not Align -- 7 Chemical Modalities: Not All Drugs Are Created Equal -- 8 Receptor Occupancy and Target Engagement -- 9 Radioligands and PET Ligands as Chemical Tools -- 10 Monoclonal Antibodies as Target Validation Tools -- 10.1 Targets Amenable to Validation by mAbs -- 10.2 The Four Pillars for In Vivo Studies -- 10.3 Quality Control of Antibody Preparation -- 10.4 Isotype -- 10.5 Selectivity -- 11 Parting Thoughts -- References -- Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies -- 1 Introduction -- 2 Genetic Background: The Importance of Strain and Substrain -- 3 Importance of Including Sex as a Variable -- 4 Pharmacokinetic and Pharmacodynamic Differences Attributable to Sex -- 5 Improving Reproducibility Through Heterogeneity -- 6 Good Research Practices in Pharmacology Include Considerations for Sex, Strain, and Age: Advantages and Limitations -- 7 Conclusions and Recommendations -- References -- Building Robustness into Translational Research -- 1 Introduction -- 2 Homogeneous vs. Heterogeneous Models -- 2.1 Animal Species and Strain -- 2.2 Sex of Animals -- 2.3 Age -- 2.4 Comorbidities -- 3 Translational Bias -- 3.1 Single Versus Multiple Pathophysiologies -- 3.2 Timing of Intervention -- 3.3 Pharmacokinetics and Dosage Choice -- 4 Conclusions -- References -- Minimum Information and Quality Standards for Conducting, Reporting, and Organizing In Vitro Research -- 1 Introduction: Why Details Matter -- 2 Efforts to Standardize In Vitro Protocols -- 2.1 The MIAME Guidelines -- 2.2 The MIBBI Portal -- 2.3 Protocol Repositories. 3 The Role of Ontologies for In Vitro Studies -- 3.1 Ontologies for Cells and Cell Lines -- 3.2 The BioAssay Ontology -- 3.3 Applications of the BAO to Bioassay Databases -- 4 Specific Examples: Quality Requirements for In Vitro Research -- 4.1 Chemical Probes -- 4.2 Cell Line Authentication -- 4.3 Antibody Validation -- 4.4 Webtools Without Minimal Information Criteria -- 4.5 General Guidelines for Reporting In Vitro Research -- 5 Open Questions and Remaining Issues -- 5.1 Guidelines vs. Standards -- 5.2 Compliance and Acceptance -- 5.3 Coordinated Efforts -- 5.4 Format and Structured Data -- 6 Concluding Remarks -- References -- Minimum Information in In Vivo Research -- 1 Introduction -- 2 General Aspects -- 3 Behavioural Experiments -- 4 Anaesthesia and Analgesia -- 5 Ex Vivo Biochemical and Histological Analysis -- 6 Histology -- 7 Ex Vivo Biochemical Analysis -- 8 Perspective -- References -- A Reckless Guide to P-values -- 1 Introduction -- 1.1 On the Role of Statistics -- 2 All About P-values -- 2.1 Hypothesis Test and Significance Test -- 2.2 Contradictory Instructions -- 2.3 Evidence Is Local -- Error Rates Are Global -- 2.4 On the Scaling of P-values -- 2.5 Power and Expected P-values -- 3 Practical Problems with P-values -- 3.1 The Significance Filter Exaggeration Machine -- 3.2 Multiple Comparisons -- 3.3 P-hacking -- 3.4 What Is a Statistical Model? -- 4 P-values and Inference -- References -- Electronic Lab Notebooks and Experimental Design Assistants -- 1 Paper vs. Electronic Lab Notebooks -- 2 Finding an eLN -- 3 Levels of Quality for eLNs -- 4 Assistance with Experimental Design -- 5 Data-Related Quality Aspects of eLNs -- 6 The LN as the Central Element of Data Management -- 7 Organizing and Documenting Experiments -- References -- Data Storage -- 1 Introduction -- 2 Data Storage Systems -- 2.1 Types of Storage. 2.2 Features of Storage Systems. Description based on publisher supplied metadata and other sources. Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. Electronic books. Michel, Martin C. Steckler, Thomas. Print version: Bespalov, Anton Good Research Practice in Non-Clinical Pharmacology and Biomedicine Cham : Springer International Publishing AG,c2020 9783030336554 ProQuest (Firm) Handbook of Experimental Pharmacology Series https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=6120896 Click to View |
language |
English |
format |
eBook |
author |
Bespalov, Anton. |
spellingShingle |
Bespalov, Anton. Good Research Practice in Non-Clinical Pharmacology and Biomedicine. Handbook of Experimental Pharmacology Series ; Intro -- Preface -- Contents -- Quality in Non-GxP Research Environment -- 1 Why Do We Need a Quality Standard in Research? -- 2 Critical Points to Consider Before Implementing a Quality Standard in Research -- 2.1 GxP or Non-GxP Standard Implementation in Research? -- 2.1.1 Diverse Quality Mind-Set -- 2.2 Resource Constraints -- 3 Non-GxP Research Standard Basics -- 3.1 Data Integrity Principles: ALCOA+ -- 3.2 Research Quality System Core Elements -- 3.2.1 Management and Governance -- 3.2.2 Secure Research Documentation and Data Management -- 3.2.3 Method and Assay Qualification -- 3.2.4 Material, Reagents and Samples Management -- 3.2.5 Facility, Equipment and Computerized System Management -- 3.2.6 Personnel and Training Records Management -- 3.2.7 Outsourcing/External Collaborations -- 3.3 Risk- and Principle-Based Quality System Assessment Approach -- 4 How Can the Community Move Forward? -- 4.1 Promoting Quality Culture -- 4.1.1 Raising Scientist Awareness, Training and Mentoring -- 4.1.2 Empowering of Associates -- 4.1.3 Incentives for Behaviours Which Support Research Quality -- 4.1.4 Promoting a Positive Error Culture -- 4.2 Creating a Recognized Quality Standard in Research: IMI Initiative - EQIPD -- 4.3 Funders Plan to Enhance Reproducibility and Transparency -- 5 Conclusion -- References -- Guidelines and Initiatives for Good Research Practice -- 1 Introduction -- 2 Guidelines and Resources Aimed at Improving Reproducibility and Robustness in Preclinical Data -- 2.1 Funders/Granting Agencies/Policy Makers -- 2.2 Publishers/Journal Groups -- 2.3 Summary of Overarching Themes -- 3 Gaps and Looking to the Future -- References -- Learning from Principles of Evidence-Based Medicine to Optimize Nonclinical Research Practices -- 1 Introduction. 2 Current Context of Nonclinical, Nonregulated Experimental Pharmacology Study Conduct: Purposes and Processes Across Sectors -- 2.1 Outcomes and Deliverables of Nonclinical Pharmacology Studies in Industry and Academia -- 2.2 Scientific Integrity: Responsible Conduct of Research and Awareness of Cognitive Bias -- 2.3 Initiating a Research Project and Documenting Prior Evidence -- 2.4 Existence and Use of Guidelines -- 2.5 Use of Experimental Bias Reduction Measures in Study Design and Execution -- 2.6 Biostatistics: Access and Use to Enable Appropriate Design of Nonclinical Pharmacology Studies -- 2.7 Data Integrity, Reporting, and Sharing -- 3 Overcoming Obstacles and Further Learning from Principles of Evidence-Based Medicine -- 3.1 Working Together to Improve Nonclinical Data Reliability -- 3.2 Enhancing Capabilities, from Training to Open Access to Data -- 4 Conclusion and Perspectives -- References -- General Principles of Preclinical Study Design -- 1 An Overview -- 2 General Scientific Methods for Designing In Vivo Experiments -- 2.1 Hypotheses and Effect Size -- 2.2 Groups, Experimental Unit and Sample Size -- 2.3 Measurements and Outcome Measures -- 2.4 Independent Variables and Analysis -- 3 Experimental Biases: Definitions and Methods to Reduce Them -- 4 Experimental Biases: Major Domains and General Principles -- 5 Existing Guidelines and How to Use Them -- 6 Exploratory and Confirmatory Research -- References -- Resolving the Tension Between Exploration and Confirmation in Preclinical Biomedical Research -- 1 Introduction -- 2 Discrimination Between Exploration and Confirmation -- 3 Exploration Must Lead to a High Rate of False Positives -- 4 The Garden of Forking Paths -- 5 Confirmation Must Weed Out the False Positives of Exploration -- 6 Exact Replication Does Not Equal Confirmation. 7 Design, Analysis, and Interpretation of Exploratory vs Confirmatory Studies -- 8 No Publication Without Confirmation? -- 9 Team Science and Preclinical Multicenter Trials -- 10 Resolving the Tension Between Exploration and Confirmation -- References -- Blinding and Randomization -- 1 Randomization and Blinding: Need for Disambiguation -- 2 Randomization -- 2.1 Varieties of Randomization -- 2.1.1 Simple Randomization -- 2.1.2 Block Randomization -- 2.1.3 Stratified Randomization -- 2.1.4 The Case of Within-Subject Study Designs -- 2.2 Tools to Conduct Randomization -- 2.3 Randomization: Exceptions and Special Cases -- 3 Blinding -- 3.1 Fit-for-Purpose Blinding -- 3.1.1 Assumed Blinding -- 3.1.2 Partial Blinding -- 3.1.3 Full Blinding -- 3.2 Implementation of Blinding -- 4 Concluding Recommendations -- References -- Out of Control? Managing Baseline Variability in Experimental Studies with Control Groups -- 1 What Are Control Groups? -- 2 Basic Considerations for Control Groups -- 2.1 Attribution of Animals to Control Groups -- 2.2 What Group Size for Control Groups? -- 2.3 Controls and Blinding -- 3 Primary Controls -- 3.1 Choosing Appropriate Control Treatments: Not All Negative Controls Are Equal -- 3.2 Vehicle Controls -- 3.3 Sham Controls -- 3.4 Non-neutral Control Groups -- 3.5 Controls for Mutant, Transgenic and Knockout Animals -- 4 Positive Controls -- 5 Secondary Controls -- 5.1 Can Baseline Values Be Used as Control? -- 5.2 Historical Control Values -- 6 When Are Control Groups Not Necessary? -- 7 Conclusion -- References -- Quality of Research Tools -- 1 Introduction -- 2 Drugs in the Twenty-First Century -- 2.1 Chemical Tools Versus Drugs -- 3 First Things First: Identity and Purity -- 3.1 The Case of Evans Blue -- 3.2 Identity and Purity of Research Reagents -- 4 Drug Specificity or Drug Selectivity? -- 5 Species Selectivity. 5.1 Animal Strain and Preclinical Efficacy Using In Vivo Models -- 5.2 Differences in Sequence of Biological Target -- 5.3 Metabolism -- 6 What We Dose Is Not Always Directly Responsible for the Effects We See -- 6.1 Conditions Where In Vitro Potency Measures Do Not Align -- 7 Chemical Modalities: Not All Drugs Are Created Equal -- 8 Receptor Occupancy and Target Engagement -- 9 Radioligands and PET Ligands as Chemical Tools -- 10 Monoclonal Antibodies as Target Validation Tools -- 10.1 Targets Amenable to Validation by mAbs -- 10.2 The Four Pillars for In Vivo Studies -- 10.3 Quality Control of Antibody Preparation -- 10.4 Isotype -- 10.5 Selectivity -- 11 Parting Thoughts -- References -- Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies -- 1 Introduction -- 2 Genetic Background: The Importance of Strain and Substrain -- 3 Importance of Including Sex as a Variable -- 4 Pharmacokinetic and Pharmacodynamic Differences Attributable to Sex -- 5 Improving Reproducibility Through Heterogeneity -- 6 Good Research Practices in Pharmacology Include Considerations for Sex, Strain, and Age: Advantages and Limitations -- 7 Conclusions and Recommendations -- References -- Building Robustness into Translational Research -- 1 Introduction -- 2 Homogeneous vs. Heterogeneous Models -- 2.1 Animal Species and Strain -- 2.2 Sex of Animals -- 2.3 Age -- 2.4 Comorbidities -- 3 Translational Bias -- 3.1 Single Versus Multiple Pathophysiologies -- 3.2 Timing of Intervention -- 3.3 Pharmacokinetics and Dosage Choice -- 4 Conclusions -- References -- Minimum Information and Quality Standards for Conducting, Reporting, and Organizing In Vitro Research -- 1 Introduction: Why Details Matter -- 2 Efforts to Standardize In Vitro Protocols -- 2.1 The MIAME Guidelines -- 2.2 The MIBBI Portal -- 2.3 Protocol Repositories. 3 The Role of Ontologies for In Vitro Studies -- 3.1 Ontologies for Cells and Cell Lines -- 3.2 The BioAssay Ontology -- 3.3 Applications of the BAO to Bioassay Databases -- 4 Specific Examples: Quality Requirements for In Vitro Research -- 4.1 Chemical Probes -- 4.2 Cell Line Authentication -- 4.3 Antibody Validation -- 4.4 Webtools Without Minimal Information Criteria -- 4.5 General Guidelines for Reporting In Vitro Research -- 5 Open Questions and Remaining Issues -- 5.1 Guidelines vs. Standards -- 5.2 Compliance and Acceptance -- 5.3 Coordinated Efforts -- 5.4 Format and Structured Data -- 6 Concluding Remarks -- References -- Minimum Information in In Vivo Research -- 1 Introduction -- 2 General Aspects -- 3 Behavioural Experiments -- 4 Anaesthesia and Analgesia -- 5 Ex Vivo Biochemical and Histological Analysis -- 6 Histology -- 7 Ex Vivo Biochemical Analysis -- 8 Perspective -- References -- A Reckless Guide to P-values -- 1 Introduction -- 1.1 On the Role of Statistics -- 2 All About P-values -- 2.1 Hypothesis Test and Significance Test -- 2.2 Contradictory Instructions -- 2.3 Evidence Is Local -- Error Rates Are Global -- 2.4 On the Scaling of P-values -- 2.5 Power and Expected P-values -- 3 Practical Problems with P-values -- 3.1 The Significance Filter Exaggeration Machine -- 3.2 Multiple Comparisons -- 3.3 P-hacking -- 3.4 What Is a Statistical Model? -- 4 P-values and Inference -- References -- Electronic Lab Notebooks and Experimental Design Assistants -- 1 Paper vs. Electronic Lab Notebooks -- 2 Finding an eLN -- 3 Levels of Quality for eLNs -- 4 Assistance with Experimental Design -- 5 Data-Related Quality Aspects of eLNs -- 6 The LN as the Central Element of Data Management -- 7 Organizing and Documenting Experiments -- References -- Data Storage -- 1 Introduction -- 2 Data Storage Systems -- 2.1 Types of Storage. 2.2 Features of Storage Systems. |
author_facet |
Bespalov, Anton. Michel, Martin C. Steckler, Thomas. |
author_variant |
a b ab |
author2 |
Michel, Martin C. Steckler, Thomas. |
author2_variant |
m c m mc mcm t s ts |
author2_role |
TeilnehmendeR TeilnehmendeR |
author_sort |
Bespalov, Anton. |
title |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
title_full |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
title_fullStr |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
title_full_unstemmed |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
title_auth |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
title_new |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
title_sort |
good research practice in non-clinical pharmacology and biomedicine. |
series |
Handbook of Experimental Pharmacology Series ; |
series2 |
Handbook of Experimental Pharmacology Series ; |
publisher |
Springer International Publishing AG, |
publishDate |
2020 |
physical |
1 online resource (424 pages) |
edition |
1st ed. |
contents |
Intro -- Preface -- Contents -- Quality in Non-GxP Research Environment -- 1 Why Do We Need a Quality Standard in Research? -- 2 Critical Points to Consider Before Implementing a Quality Standard in Research -- 2.1 GxP or Non-GxP Standard Implementation in Research? -- 2.1.1 Diverse Quality Mind-Set -- 2.2 Resource Constraints -- 3 Non-GxP Research Standard Basics -- 3.1 Data Integrity Principles: ALCOA+ -- 3.2 Research Quality System Core Elements -- 3.2.1 Management and Governance -- 3.2.2 Secure Research Documentation and Data Management -- 3.2.3 Method and Assay Qualification -- 3.2.4 Material, Reagents and Samples Management -- 3.2.5 Facility, Equipment and Computerized System Management -- 3.2.6 Personnel and Training Records Management -- 3.2.7 Outsourcing/External Collaborations -- 3.3 Risk- and Principle-Based Quality System Assessment Approach -- 4 How Can the Community Move Forward? -- 4.1 Promoting Quality Culture -- 4.1.1 Raising Scientist Awareness, Training and Mentoring -- 4.1.2 Empowering of Associates -- 4.1.3 Incentives for Behaviours Which Support Research Quality -- 4.1.4 Promoting a Positive Error Culture -- 4.2 Creating a Recognized Quality Standard in Research: IMI Initiative - EQIPD -- 4.3 Funders Plan to Enhance Reproducibility and Transparency -- 5 Conclusion -- References -- Guidelines and Initiatives for Good Research Practice -- 1 Introduction -- 2 Guidelines and Resources Aimed at Improving Reproducibility and Robustness in Preclinical Data -- 2.1 Funders/Granting Agencies/Policy Makers -- 2.2 Publishers/Journal Groups -- 2.3 Summary of Overarching Themes -- 3 Gaps and Looking to the Future -- References -- Learning from Principles of Evidence-Based Medicine to Optimize Nonclinical Research Practices -- 1 Introduction. 2 Current Context of Nonclinical, Nonregulated Experimental Pharmacology Study Conduct: Purposes and Processes Across Sectors -- 2.1 Outcomes and Deliverables of Nonclinical Pharmacology Studies in Industry and Academia -- 2.2 Scientific Integrity: Responsible Conduct of Research and Awareness of Cognitive Bias -- 2.3 Initiating a Research Project and Documenting Prior Evidence -- 2.4 Existence and Use of Guidelines -- 2.5 Use of Experimental Bias Reduction Measures in Study Design and Execution -- 2.6 Biostatistics: Access and Use to Enable Appropriate Design of Nonclinical Pharmacology Studies -- 2.7 Data Integrity, Reporting, and Sharing -- 3 Overcoming Obstacles and Further Learning from Principles of Evidence-Based Medicine -- 3.1 Working Together to Improve Nonclinical Data Reliability -- 3.2 Enhancing Capabilities, from Training to Open Access to Data -- 4 Conclusion and Perspectives -- References -- General Principles of Preclinical Study Design -- 1 An Overview -- 2 General Scientific Methods for Designing In Vivo Experiments -- 2.1 Hypotheses and Effect Size -- 2.2 Groups, Experimental Unit and Sample Size -- 2.3 Measurements and Outcome Measures -- 2.4 Independent Variables and Analysis -- 3 Experimental Biases: Definitions and Methods to Reduce Them -- 4 Experimental Biases: Major Domains and General Principles -- 5 Existing Guidelines and How to Use Them -- 6 Exploratory and Confirmatory Research -- References -- Resolving the Tension Between Exploration and Confirmation in Preclinical Biomedical Research -- 1 Introduction -- 2 Discrimination Between Exploration and Confirmation -- 3 Exploration Must Lead to a High Rate of False Positives -- 4 The Garden of Forking Paths -- 5 Confirmation Must Weed Out the False Positives of Exploration -- 6 Exact Replication Does Not Equal Confirmation. 7 Design, Analysis, and Interpretation of Exploratory vs Confirmatory Studies -- 8 No Publication Without Confirmation? -- 9 Team Science and Preclinical Multicenter Trials -- 10 Resolving the Tension Between Exploration and Confirmation -- References -- Blinding and Randomization -- 1 Randomization and Blinding: Need for Disambiguation -- 2 Randomization -- 2.1 Varieties of Randomization -- 2.1.1 Simple Randomization -- 2.1.2 Block Randomization -- 2.1.3 Stratified Randomization -- 2.1.4 The Case of Within-Subject Study Designs -- 2.2 Tools to Conduct Randomization -- 2.3 Randomization: Exceptions and Special Cases -- 3 Blinding -- 3.1 Fit-for-Purpose Blinding -- 3.1.1 Assumed Blinding -- 3.1.2 Partial Blinding -- 3.1.3 Full Blinding -- 3.2 Implementation of Blinding -- 4 Concluding Recommendations -- References -- Out of Control? Managing Baseline Variability in Experimental Studies with Control Groups -- 1 What Are Control Groups? -- 2 Basic Considerations for Control Groups -- 2.1 Attribution of Animals to Control Groups -- 2.2 What Group Size for Control Groups? -- 2.3 Controls and Blinding -- 3 Primary Controls -- 3.1 Choosing Appropriate Control Treatments: Not All Negative Controls Are Equal -- 3.2 Vehicle Controls -- 3.3 Sham Controls -- 3.4 Non-neutral Control Groups -- 3.5 Controls for Mutant, Transgenic and Knockout Animals -- 4 Positive Controls -- 5 Secondary Controls -- 5.1 Can Baseline Values Be Used as Control? -- 5.2 Historical Control Values -- 6 When Are Control Groups Not Necessary? -- 7 Conclusion -- References -- Quality of Research Tools -- 1 Introduction -- 2 Drugs in the Twenty-First Century -- 2.1 Chemical Tools Versus Drugs -- 3 First Things First: Identity and Purity -- 3.1 The Case of Evans Blue -- 3.2 Identity and Purity of Research Reagents -- 4 Drug Specificity or Drug Selectivity? -- 5 Species Selectivity. 5.1 Animal Strain and Preclinical Efficacy Using In Vivo Models -- 5.2 Differences in Sequence of Biological Target -- 5.3 Metabolism -- 6 What We Dose Is Not Always Directly Responsible for the Effects We See -- 6.1 Conditions Where In Vitro Potency Measures Do Not Align -- 7 Chemical Modalities: Not All Drugs Are Created Equal -- 8 Receptor Occupancy and Target Engagement -- 9 Radioligands and PET Ligands as Chemical Tools -- 10 Monoclonal Antibodies as Target Validation Tools -- 10.1 Targets Amenable to Validation by mAbs -- 10.2 The Four Pillars for In Vivo Studies -- 10.3 Quality Control of Antibody Preparation -- 10.4 Isotype -- 10.5 Selectivity -- 11 Parting Thoughts -- References -- Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies -- 1 Introduction -- 2 Genetic Background: The Importance of Strain and Substrain -- 3 Importance of Including Sex as a Variable -- 4 Pharmacokinetic and Pharmacodynamic Differences Attributable to Sex -- 5 Improving Reproducibility Through Heterogeneity -- 6 Good Research Practices in Pharmacology Include Considerations for Sex, Strain, and Age: Advantages and Limitations -- 7 Conclusions and Recommendations -- References -- Building Robustness into Translational Research -- 1 Introduction -- 2 Homogeneous vs. Heterogeneous Models -- 2.1 Animal Species and Strain -- 2.2 Sex of Animals -- 2.3 Age -- 2.4 Comorbidities -- 3 Translational Bias -- 3.1 Single Versus Multiple Pathophysiologies -- 3.2 Timing of Intervention -- 3.3 Pharmacokinetics and Dosage Choice -- 4 Conclusions -- References -- Minimum Information and Quality Standards for Conducting, Reporting, and Organizing In Vitro Research -- 1 Introduction: Why Details Matter -- 2 Efforts to Standardize In Vitro Protocols -- 2.1 The MIAME Guidelines -- 2.2 The MIBBI Portal -- 2.3 Protocol Repositories. 3 The Role of Ontologies for In Vitro Studies -- 3.1 Ontologies for Cells and Cell Lines -- 3.2 The BioAssay Ontology -- 3.3 Applications of the BAO to Bioassay Databases -- 4 Specific Examples: Quality Requirements for In Vitro Research -- 4.1 Chemical Probes -- 4.2 Cell Line Authentication -- 4.3 Antibody Validation -- 4.4 Webtools Without Minimal Information Criteria -- 4.5 General Guidelines for Reporting In Vitro Research -- 5 Open Questions and Remaining Issues -- 5.1 Guidelines vs. Standards -- 5.2 Compliance and Acceptance -- 5.3 Coordinated Efforts -- 5.4 Format and Structured Data -- 6 Concluding Remarks -- References -- Minimum Information in In Vivo Research -- 1 Introduction -- 2 General Aspects -- 3 Behavioural Experiments -- 4 Anaesthesia and Analgesia -- 5 Ex Vivo Biochemical and Histological Analysis -- 6 Histology -- 7 Ex Vivo Biochemical Analysis -- 8 Perspective -- References -- A Reckless Guide to P-values -- 1 Introduction -- 1.1 On the Role of Statistics -- 2 All About P-values -- 2.1 Hypothesis Test and Significance Test -- 2.2 Contradictory Instructions -- 2.3 Evidence Is Local -- Error Rates Are Global -- 2.4 On the Scaling of P-values -- 2.5 Power and Expected P-values -- 3 Practical Problems with P-values -- 3.1 The Significance Filter Exaggeration Machine -- 3.2 Multiple Comparisons -- 3.3 P-hacking -- 3.4 What Is a Statistical Model? -- 4 P-values and Inference -- References -- Electronic Lab Notebooks and Experimental Design Assistants -- 1 Paper vs. Electronic Lab Notebooks -- 2 Finding an eLN -- 3 Levels of Quality for eLNs -- 4 Assistance with Experimental Design -- 5 Data-Related Quality Aspects of eLNs -- 6 The LN as the Central Element of Data Management -- 7 Organizing and Documenting Experiments -- References -- Data Storage -- 1 Introduction -- 2 Data Storage Systems -- 2.1 Types of Storage. 2.2 Features of Storage Systems. |
isbn |
9783030336561 9783030336554 |
callnumber-first |
R - Medicine |
callnumber-subject |
RM - Therapeutics and Pharmacology |
callnumber-label |
RM300-666 |
callnumber-sort |
RM 3300 3666 |
genre |
Electronic books. |
genre_facet |
Electronic books. |
url |
https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=6120896 |
illustrated |
Not Illustrated |
oclc_num |
1143621169 |
work_keys_str_mv |
AT bespalovanton goodresearchpracticeinnonclinicalpharmacologyandbiomedicine AT michelmartinc goodresearchpracticeinnonclinicalpharmacologyandbiomedicine AT stecklerthomas goodresearchpracticeinnonclinicalpharmacologyandbiomedicine |
status_str |
n |
ids_txt_mv |
(MiAaPQ)5006120896 (Au-PeEL)EBL6120896 (OCoLC)1143621169 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Handbook of Experimental Pharmacology Series ; v.257 |
is_hierarchy_title |
Good Research Practice in Non-Clinical Pharmacology and Biomedicine. |
container_title |
Handbook of Experimental Pharmacology Series ; v.257 |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
marc_error |
Info : Unimarc and ISO-8859-1 translations identical, choosing ISO-8859-1. --- [ 856 : z ] |
_version_ |
1792331055701688320 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>11052nam a22004813i 4500</leader><controlfield tag="001">5006120896</controlfield><controlfield tag="003">MiAaPQ</controlfield><controlfield tag="005">20240229073833.0</controlfield><controlfield tag="006">m o d | </controlfield><controlfield tag="007">cr cnu||||||||</controlfield><controlfield tag="008">240229s2020 xx o ||||0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783030336561</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9783030336554</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(MiAaPQ)5006120896</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(Au-PeEL)EBL6120896</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1143621169</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MiAaPQ</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">MiAaPQ</subfield><subfield code="d">MiAaPQ</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM300-666</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bespalov, Anton.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Good Research Practice in Non-Clinical Pharmacology and Biomedicine.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer International Publishing AG,</subfield><subfield code="c">2020.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">Ã2020.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (424 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of Experimental Pharmacology Series ;</subfield><subfield code="v">v.257</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- Preface -- Contents -- Quality in Non-GxP Research Environment -- 1 Why Do We Need a Quality Standard in Research? -- 2 Critical Points to Consider Before Implementing a Quality Standard in Research -- 2.1 GxP or Non-GxP Standard Implementation in Research? -- 2.1.1 Diverse Quality Mind-Set -- 2.2 Resource Constraints -- 3 Non-GxP Research Standard Basics -- 3.1 Data Integrity Principles: ALCOA+ -- 3.2 Research Quality System Core Elements -- 3.2.1 Management and Governance -- 3.2.2 Secure Research Documentation and Data Management -- 3.2.3 Method and Assay Qualification -- 3.2.4 Material, Reagents and Samples Management -- 3.2.5 Facility, Equipment and Computerized System Management -- 3.2.6 Personnel and Training Records Management -- 3.2.7 Outsourcing/External Collaborations -- 3.3 Risk- and Principle-Based Quality System Assessment Approach -- 4 How Can the Community Move Forward? -- 4.1 Promoting Quality Culture -- 4.1.1 Raising Scientist Awareness, Training and Mentoring -- 4.1.2 Empowering of Associates -- 4.1.3 Incentives for Behaviours Which Support Research Quality -- 4.1.4 Promoting a Positive Error Culture -- 4.2 Creating a Recognized Quality Standard in Research: IMI Initiative - EQIPD -- 4.3 Funders Plan to Enhance Reproducibility and Transparency -- 5 Conclusion -- References -- Guidelines and Initiatives for Good Research Practice -- 1 Introduction -- 2 Guidelines and Resources Aimed at Improving Reproducibility and Robustness in Preclinical Data -- 2.1 Funders/Granting Agencies/Policy Makers -- 2.2 Publishers/Journal Groups -- 2.3 Summary of Overarching Themes -- 3 Gaps and Looking to the Future -- References -- Learning from Principles of Evidence-Based Medicine to Optimize Nonclinical Research Practices -- 1 Introduction.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2 Current Context of Nonclinical, Nonregulated Experimental Pharmacology Study Conduct: Purposes and Processes Across Sectors -- 2.1 Outcomes and Deliverables of Nonclinical Pharmacology Studies in Industry and Academia -- 2.2 Scientific Integrity: Responsible Conduct of Research and Awareness of Cognitive Bias -- 2.3 Initiating a Research Project and Documenting Prior Evidence -- 2.4 Existence and Use of Guidelines -- 2.5 Use of Experimental Bias Reduction Measures in Study Design and Execution -- 2.6 Biostatistics: Access and Use to Enable Appropriate Design of Nonclinical Pharmacology Studies -- 2.7 Data Integrity, Reporting, and Sharing -- 3 Overcoming Obstacles and Further Learning from Principles of Evidence-Based Medicine -- 3.1 Working Together to Improve Nonclinical Data Reliability -- 3.2 Enhancing Capabilities, from Training to Open Access to Data -- 4 Conclusion and Perspectives -- References -- General Principles of Preclinical Study Design -- 1 An Overview -- 2 General Scientific Methods for Designing In Vivo Experiments -- 2.1 Hypotheses and Effect Size -- 2.2 Groups, Experimental Unit and Sample Size -- 2.3 Measurements and Outcome Measures -- 2.4 Independent Variables and Analysis -- 3 Experimental Biases: Definitions and Methods to Reduce Them -- 4 Experimental Biases: Major Domains and General Principles -- 5 Existing Guidelines and How to Use Them -- 6 Exploratory and Confirmatory Research -- References -- Resolving the Tension Between Exploration and Confirmation in Preclinical Biomedical Research -- 1 Introduction -- 2 Discrimination Between Exploration and Confirmation -- 3 Exploration Must Lead to a High Rate of False Positives -- 4 The Garden of Forking Paths -- 5 Confirmation Must Weed Out the False Positives of Exploration -- 6 Exact Replication Does Not Equal Confirmation.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">7 Design, Analysis, and Interpretation of Exploratory vs Confirmatory Studies -- 8 No Publication Without Confirmation? -- 9 Team Science and Preclinical Multicenter Trials -- 10 Resolving the Tension Between Exploration and Confirmation -- References -- Blinding and Randomization -- 1 Randomization and Blinding: Need for Disambiguation -- 2 Randomization -- 2.1 Varieties of Randomization -- 2.1.1 Simple Randomization -- 2.1.2 Block Randomization -- 2.1.3 Stratified Randomization -- 2.1.4 The Case of Within-Subject Study Designs -- 2.2 Tools to Conduct Randomization -- 2.3 Randomization: Exceptions and Special Cases -- 3 Blinding -- 3.1 Fit-for-Purpose Blinding -- 3.1.1 Assumed Blinding -- 3.1.2 Partial Blinding -- 3.1.3 Full Blinding -- 3.2 Implementation of Blinding -- 4 Concluding Recommendations -- References -- Out of Control? Managing Baseline Variability in Experimental Studies with Control Groups -- 1 What Are Control Groups? -- 2 Basic Considerations for Control Groups -- 2.1 Attribution of Animals to Control Groups -- 2.2 What Group Size for Control Groups? -- 2.3 Controls and Blinding -- 3 Primary Controls -- 3.1 Choosing Appropriate Control Treatments: Not All Negative Controls Are Equal -- 3.2 Vehicle Controls -- 3.3 Sham Controls -- 3.4 Non-neutral Control Groups -- 3.5 Controls for Mutant, Transgenic and Knockout Animals -- 4 Positive Controls -- 5 Secondary Controls -- 5.1 Can Baseline Values Be Used as Control? -- 5.2 Historical Control Values -- 6 When Are Control Groups Not Necessary? -- 7 Conclusion -- References -- Quality of Research Tools -- 1 Introduction -- 2 Drugs in the Twenty-First Century -- 2.1 Chemical Tools Versus Drugs -- 3 First Things First: Identity and Purity -- 3.1 The Case of Evans Blue -- 3.2 Identity and Purity of Research Reagents -- 4 Drug Specificity or Drug Selectivity? -- 5 Species Selectivity.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.1 Animal Strain and Preclinical Efficacy Using In Vivo Models -- 5.2 Differences in Sequence of Biological Target -- 5.3 Metabolism -- 6 What We Dose Is Not Always Directly Responsible for the Effects We See -- 6.1 Conditions Where In Vitro Potency Measures Do Not Align -- 7 Chemical Modalities: Not All Drugs Are Created Equal -- 8 Receptor Occupancy and Target Engagement -- 9 Radioligands and PET Ligands as Chemical Tools -- 10 Monoclonal Antibodies as Target Validation Tools -- 10.1 Targets Amenable to Validation by mAbs -- 10.2 The Four Pillars for In Vivo Studies -- 10.3 Quality Control of Antibody Preparation -- 10.4 Isotype -- 10.5 Selectivity -- 11 Parting Thoughts -- References -- Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies -- 1 Introduction -- 2 Genetic Background: The Importance of Strain and Substrain -- 3 Importance of Including Sex as a Variable -- 4 Pharmacokinetic and Pharmacodynamic Differences Attributable to Sex -- 5 Improving Reproducibility Through Heterogeneity -- 6 Good Research Practices in Pharmacology Include Considerations for Sex, Strain, and Age: Advantages and Limitations -- 7 Conclusions and Recommendations -- References -- Building Robustness into Translational Research -- 1 Introduction -- 2 Homogeneous vs. Heterogeneous Models -- 2.1 Animal Species and Strain -- 2.2 Sex of Animals -- 2.3 Age -- 2.4 Comorbidities -- 3 Translational Bias -- 3.1 Single Versus Multiple Pathophysiologies -- 3.2 Timing of Intervention -- 3.3 Pharmacokinetics and Dosage Choice -- 4 Conclusions -- References -- Minimum Information and Quality Standards for Conducting, Reporting, and Organizing In Vitro Research -- 1 Introduction: Why Details Matter -- 2 Efforts to Standardize In Vitro Protocols -- 2.1 The MIAME Guidelines -- 2.2 The MIBBI Portal -- 2.3 Protocol Repositories.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3 The Role of Ontologies for In Vitro Studies -- 3.1 Ontologies for Cells and Cell Lines -- 3.2 The BioAssay Ontology -- 3.3 Applications of the BAO to Bioassay Databases -- 4 Specific Examples: Quality Requirements for In Vitro Research -- 4.1 Chemical Probes -- 4.2 Cell Line Authentication -- 4.3 Antibody Validation -- 4.4 Webtools Without Minimal Information Criteria -- 4.5 General Guidelines for Reporting In Vitro Research -- 5 Open Questions and Remaining Issues -- 5.1 Guidelines vs. Standards -- 5.2 Compliance and Acceptance -- 5.3 Coordinated Efforts -- 5.4 Format and Structured Data -- 6 Concluding Remarks -- References -- Minimum Information in In Vivo Research -- 1 Introduction -- 2 General Aspects -- 3 Behavioural Experiments -- 4 Anaesthesia and Analgesia -- 5 Ex Vivo Biochemical and Histological Analysis -- 6 Histology -- 7 Ex Vivo Biochemical Analysis -- 8 Perspective -- References -- A Reckless Guide to P-values -- 1 Introduction -- 1.1 On the Role of Statistics -- 2 All About P-values -- 2.1 Hypothesis Test and Significance Test -- 2.2 Contradictory Instructions -- 2.3 Evidence Is Local -- Error Rates Are Global -- 2.4 On the Scaling of P-values -- 2.5 Power and Expected P-values -- 3 Practical Problems with P-values -- 3.1 The Significance Filter Exaggeration Machine -- 3.2 Multiple Comparisons -- 3.3 P-hacking -- 3.4 What Is a Statistical Model? -- 4 P-values and Inference -- References -- Electronic Lab Notebooks and Experimental Design Assistants -- 1 Paper vs. Electronic Lab Notebooks -- 2 Finding an eLN -- 3 Levels of Quality for eLNs -- 4 Assistance with Experimental Design -- 5 Data-Related Quality Aspects of eLNs -- 6 The LN as the Central Element of Data Management -- 7 Organizing and Documenting Experiments -- References -- Data Storage -- 1 Introduction -- 2 Data Storage Systems -- 2.1 Types of Storage.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.2 Features of Storage Systems.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="590" ind1=" " ind2=" "><subfield code="a">Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. </subfield></datafield><datafield tag="655" ind1=" " ind2="4"><subfield code="a">Electronic books.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Michel, Martin C.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Steckler, Thomas.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Bespalov, Anton</subfield><subfield code="t">Good Research Practice in Non-Clinical Pharmacology and Biomedicine</subfield><subfield code="d">Cham : Springer International Publishing AG,c2020</subfield><subfield code="z">9783030336554</subfield></datafield><datafield tag="797" ind1="2" ind2=" "><subfield code="a">ProQuest (Firm)</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of Experimental Pharmacology Series</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=6120896</subfield><subfield code="z">Click to View</subfield></datafield></record></collection> |